Core Viewpoint - Arcturus Therapeutics is positioned as a high-potential biotech stock under $10, with expectations of a 404% increase by 2026 due to promising clinical data and a clear development pipeline [1]. Company Overview - Arcturus Therapeutics (ARCT) focuses on developing mRNA-based medicines and vaccines, aiming to address root causes of diseases rather than just symptoms [2]. - The company is currently valued at $194.3 million and experienced a 64% decline in stock value last year, contrasting with a 16% gain in the S&P 500 Index, although the stock has risen by 10% this year [2]. Product Development and Pipeline - Arcturus has developed the world's first approved self-amplifying mRNA Covid-19 vaccine, KOSTAIVE, and is collaborating on mRNA vaccines for Covid-19 variants and pandemic influenza [3]. - The company is advancing ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis (CF), with interim Phase 2 data showing safety and reductions in mucus burden in patients [4]. - A 12-week safety and preliminary efficacy study for ARCT-032 is planned for the first half of 2026, with a higher dose cohort being enrolled to refine the dose-response profile [5]. Additional Therapeutic Developments - Arcturus is also developing ARCT-810 for ornithine transcarbamylase (OTC) deficiency, with plans to collaborate with regulatory agencies on trial designs in 2026 [6]. - The company's mRNA platform is validated through its vaccine programs, with significant immune responses and safety profiles observed in ongoing trials for Covid-19 and pandemic influenza candidates [6].

Group 1 - The Long Triangle capital market has initiated a high-tech "first stock" competition in 2026, focusing on sectors like artificial intelligence, integrated circuits, and biomedicine, highlighting a comprehensive contest of innovation ecology, industrial resilience, and institutional precision [1] - Suzhou's Kunshan Ruibo Biotech became Jiangsu's and Suzhou's first stock of 2026, raising over 1.8 billion HKD for clinical research and technology upgrades, with its core pipeline targeting chronic diseases [2][3] - In 2025, over 90% of newly listed companies in Suzhou were high-tech enterprises, indicating a deepening integration of technology, industry, and finance [3] Group 2 - Shanghai experienced a surge in AI-related IPOs, with five companies listed in a month, showcasing its strength as a source of technological innovation [4][5] - The AI industry in Shanghai is characterized by a complete vertical integration from computing power to application, with companies like Nebula and Wallen Technology leading the charge [5] - Shanghai's integrated circuit industry is robust, with over 1,200 companies and a projected revenue of over 460 billion CNY in 2025, supporting the growth of AI enterprises [5][6] Group 3 - Zhejiang's IPO landscape is developing, with companies like Zhoushan Morning Light Motor poised for listing, focusing on micro-motor technology [7][8] - Anhui is targeting the semiconductor sector, with Hefei Changxin Technology's IPO application aiming to raise 29.5 billion CNY for memory technology upgrades, marking a significant entry into the market [9][10] - The semiconductor industry in Anhui is expanding, with companies like Fuda Semiconductor also initiating IPO processes, indicating a growing ecosystem [10]

Group 1 - Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies, currently trading on NASDAQ under the symbol LINE [1] - Scotiabank has set a price target of $39 for LINE, indicating a potential upside of approximately 7.04% from its current trading price of $36.55 [1][5] - The company has achieved a significant milestone by receiving a novel induced pluripotent stem cell (iPSC) line with hypoimmunity edits in collaboration with Factor Bioscience Inc., which is crucial for developing allogeneic cell therapies [2][5] Group 2 - The current trading price of LINE is $36.55, reflecting a slight decrease of 0.02 or approximately -0.05%, with fluctuations between a low of $35.70 and a high of $37.08 today [3] - Over the past year, LINE has experienced a high of $62.30 and a low of $32.45, indicating significant market volatility [3][5] - Lineage's market capitalization is approximately $8.35 billion, with a trading volume of 365,212 shares, suggesting moderate investor interest and activity [4]

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to change the Company’s jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in the United States. The Company believes it is important to clearly communicate the strategic and operational reasons underlying this proposal as Oncolyt ...

NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra ...

Core Insights - Senti Biosciences, Inc. is participating in the Biotech Showcase 2026, highlighting its focus on next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The panel presentation titled "Engineering the Future: Advances in Cell and Gene Therapies" will take place on January 13, 2026, at 8:00 AM PST [2] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to developing innovative cell and gene therapies for patients with incurable diseases [4] - The company utilizes a synthetic biology platform to engineer Gene Circuits aimed at precisely targeting and killing cancer cells while sparing healthy cells [4] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Industry Context - The Biotech Showcase serves as a significant investor and networking conference for biotechnology and life sciences companies, providing a platform for presenting to investors and pharmaceutical executives [3] - This event is recognized for setting the tone for the biotechnology sector in the upcoming year, featuring multiple tracks, plenary sessions, and networking opportunities [3]

Core Insights - Tenaya Therapeutics aims to build on positive interim results from its TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) in 2025, with plans to report longer-term follow-up data in 2026 [1][3] - The company raised $60 million in Q4 2025 to support its operations through mid-2027 [1][7] Clinical Development Updates - Tenaya expects to share interim data for Cohort 2 of the MyPEAK-1 trial and updates from Cohort 1 in the first half of 2026, with one-year data for Cohort 1 and two-year data for Cohort 2 anticipated in the second half of 2026 [6][12] - The MyPEAK-1 trial has shown that TN-201 was well tolerated, with no dose-limiting toxicities and significant increases in MyBP-C protein levels observed [6][8] - The RIDGE-1 trial for TN-401 is also progressing, with initial positive data reported and plans for further patient enrollment following a review by the Data Safety Monitoring Board (DSMB) [12][14] Financial Position - As of Q3 2025, Tenaya had $56.3 million in cash and equivalents, and the additional $60 million raised is expected to fund operations through mid-2027 [7][1] Regulatory and Strategic Plans - The company plans to pursue regulatory alignment for its lead gene therapy programs, TN-201 and TN-401, throughout 2026 [1][12] - Tenaya's gene therapies have received various designations from the FDA, including Fast Track and Orphan Drug designations, indicating their potential significance in treating rare diseases [8][11]

As you know, MoonLake Immunotherapeutics ( MLTX ) stock had a pretty rough 2025. And we're only now starting to see it recover from the lows of the $6 range we saw it drop to in lateI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind d ...

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds ...